REGISTER
Shouyao’s Conteltinib Approved in China for ALK+ NSCLC
On June 11, China’s NMPA approved Shouyao Holding’s conteltinib (CT-707, Qianzaoze®) as a monotherapy for ALK-positive locally advanced or metastatic NSCLC in patients without prior ALK inhibitor therapy. In a Phase III trial of 414 patients, conteltinib demonstrated significantly improved PFS vs. crizotinib with a favorable safety profile. ALK fusions occur in 5-7% of NSCLC patients. This approval adds a new targeted option for this population.

On June 11, the official website of the National Medical Products Administration (NMPA) showed that conteltinib granules (CT-707, formerly known as Kangtaitinib, brand name: Qianzaoze®), independently developed by Shouyao Holding Co., Ltd., have been approved for marketing as a monotherapy for the treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have not previously received anaplastic lymphoma kinase (ALK) inhibitor therapy.

In the first half of 2024, the complete data readout from the pivotal Phase III clinical trial of conteltinib in patients with ALK-positive NSCLC was released, with the primary endpoint results meeting the pre-specified superiority criteria.

This pivotal Phase III trial enrolled a total of 414 patients with ALK-positive advanced NSCLC who had received at most one prior line of chemotherapy and no prior ALK inhibitor therapy. The trial was designed to compare the efficacy and safety of conteltinib versus crizotinib in these patients. The primary endpoint was progression-free survival (PFS) assessed by an independent radiology review committee. Secondary endpoints included investigator-assessed PFS, objective response rate (ORR) by both investigator and independent review, duration of response (DOR), and overall survival (OS), among others.

The study confirmed that patients in the conteltinib arm achieved a statistically significant and clinically meaningful improvement in PFS compared to the control arm. Conteltinib also demonstrated a distinctively favorable safety profile.

Lung cancer is the most common cancer globally and in China. Based on different pathological types, lung cancer can be broadly classified into NSCLC and small cell lung cancer (SCLC), with NSCLC accounting for approximately 85% of all lung cancer cases. Among these, the ALK gene (fusion or rearrangement) is a common driver gene in NSCLC. Relevant data indicate that ALK gene fusion mutations are present in approximately 5% to 7% of the NSCLC patient population. Given the large patient population with NSCLC, the number of ALK fusion-positive patients is considerable. In clinical practice, as precision targeted therapies for ALK gene fusion mutations, ALK small-molecule inhibitors have brought significant clinical benefits to this patient group and have been included as a first-line treatment option in treatment guidelines established by the Chinese Society of Clinical Oncology (CSCO) and the National Comprehensive Cancer Network (NCCN).

0
0
Loading